Cochrane · systematic review · CD013767
Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias
Foong, WC, Loh, CK, Ho, JJ, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
26
current version
GRADE rated
13
No studies
13
Included studies
NR
No studies 13 · 50%Ungraded 0 · 0%Very low 10 · 38.5%Low 3 · 11.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Single foetal haemoglobin inducer at any dose or duration compared with usual care or placebo
Population: people with non‐transfusion‐dependent β‐thalassaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of transfusion (transfused volume/year) Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo | no estimate extracted | NR | No studies |
Transfusion‐free interval (days) Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo | no estimate extracted | NR | No studies |
Haemoglobin (g/dL) Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo | no estimate extracted | 1 study · 35 participants | Very low Downgraded: imprecision, indirectness |
HbF (%) Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo | no estimate extracted | 1 study · 35 participants | Very low Downgraded: imprecision, indirectness |
QoL Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo | no estimate extracted | NR | No studies |
Adverse events Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo | no estimate extracted | 2 studies · 56 participants | Very low Downgraded: imprecision, indirectness |
Single foetal haemoglobin inducer at any dose or duration compared with another foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia
Population: people with non‐transfusion‐dependent β‐thalassaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of transfusion (transfused volume/year) Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Transfusion‐free interval (days) Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Haemoglobin (g/dL) Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer | no estimate extracted | 4 studies · 118 participants | Low Downgraded: imprecision |
HbF (%) Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer | no estimate extracted | 3 studies · 84 participants | Low Downgraded: imprecision |
QoL Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Adverse events Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer | no estimate extracted | 4 studies · 118 participants | Very low Downgraded: risk of bias, imprecision |
One dose or dose regimen of a foetal haemoglobin inducer compared with another dose or dose regimen of the same foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia
Population: people with non‐transfusion‐dependent β‐thalassaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of transfusion (transfused volume/ year) One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Transfusion‐free interval (days) One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Haemoglobin (g/dL) One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer | no estimate extracted | 1 study · 61 participants | Very low Downgraded: risk of bias, imprecision |
HbF (%) One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer | no estimate extracted | 1 study · 61 participants | Very low Downgraded: risk of bias, imprecision |
QoL One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Adverse events One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer | no estimate extracted | 2 studies · 82 participants | Very low Downgraded: imprecision, indirectness |
Neutropenia (WBC < 1 × 103/μL, ANC < 0.5 × 103/μL) One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer | RR 9.93 [1.34, 73.67] | 1 study · 61 participants | Very low Downgraded: imprecision, indirectness |
Thrombocytopenia (platelet count < 50 × 103/μL) One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer | RR 3.68 [1.12, 12.07] | 1 study · 61 participants | Very low Downgraded: imprecision, indirectness |
Two or more foetal haemoglobin inducers at any dose or duration compared with a usual management protocol, placebo or a single foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia
Population: people with non‐transfusion‐dependent β‐thalassaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of transfusion (transfused volume/year) Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Transfusion‐free interval (days) Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Haemoglobin level (g/dL) Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer | no estimate extracted | 1 study · 54 participants | Low Downgraded: imprecision |
HbF levels (%) Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer | no estimate extracted | NR | No studies |
QoL Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer | no estimate extracted | NR | No studies |
Adverse events Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer | no estimate extracted | 2 studies · 104 participants | Very low Downgraded: risk of bias, imprecision |